cancerspeculator let me add a little more meat to your potatoes .....LOXO Briefing Document for the 29 June 2016 Oncologic Drugs Advisory Committee Pediatric Subcommittee on the FDA website, go to FDA "drugs" type in LOXO-101 in the search bar, a 49 page document on LOXO-101 should be your 1st hit.
Something tells me, the company is in buyout talks. When the buyout price is in the 8.00-9.00 range the shareholders will be jumping for joy as they are mostly in the red as we speak. Investment Psychology at its best.
Short interest went down by 2 million shares, now sitting at 21.3 million shares short.
Also the lowest short interest in the last 12 months, tomorrow might be a good time to start covering :)
An SEC form similar to the Schedule 13D used to report a party's ownership of stock that is over 5% of the company. Schedule 13G is shorter and requires less information from the filing party. Ownership of over 5% in a publicly-traded stock is considered to be significant ownership, and therefore must be reported to the public.
BlackRock Inc was a buyer, contrary to some of the previous post. They hold 6.5%of the float as Redmile holds close to 16% of the float
I did my part (again) while the pipeline is strong , the leadership has definitely let down the shareholders.
I did mention the continuous cheerleading by the CEO with his favorite 2 phrases "UPCOMING CATALYST" and his new phrase "NEXY VALUE DRIVER" with added no value what so ever. Go to the archives and listen for yourself.
We have given him ample of time to produce "shareholder value" it might be time for the institutions to put some pressure on Mr Squarer and have him replaced. JMHO
• Loxo's collaboration with Array BioPharma continues to generate compelling and differentiated chemical matter. Loxo has used its multi-target, prioritize-by-success collaboration structure to focus on RET and FGFR.
Clinical Validation for LOXO-101 Published in Cancer Discovery
1) Yesterdays SEC 8K filing aroused my suspicious, besides increasing their cash position, it moved 33 employees to a new company, the other option would be laying off all unneeded employees. Especially if the acquirer already has a (CMC) Chemistry, Manufacturing and Controls Division . For "INSTATANCE" AstraZeneca already has a CMC Unit, no need to duplicate . I can see the acquirer absorbing the remainder of the ARRAY employees (150).
2) With Institutional Ownership at 102% of float , makes me wonder what does "ALL" the big money know that the retail investor is not aware of ? The last stock I owned with 90% institutional Ownership was HGSI and it was bought out shortly there after.
Of course this is just my humble opinion, time will tell. Like most of you, I rather see the pipeline mature and commercialize their products, than a buyout in the $18.00-$22.00 range.
Opinions ? Ideas ?
MEK162 shows signs of clinical efficacy in pts with biliary tract cancer MEK162 has an acceptable safety profile at 60 mg BID Central serous-like retinopathy was manageable with dose modifications MEK162 has desirable PK propertiesthat were equivalent to that observed in prior studies An additional expansion cohort is ongoing in ptswith KRAS-or BRAF-mutant metastatic colorectal cancer
on the ASCO Website, you might also be able to google it. Waiting for a BIG Monday /Tuesday
still buying arry , 89% institutional ownership and look at their pipeline, not to mention royalties only will pay arry